Tasimelteon
Tasimelteon is a selective melatonin receptor agonist (MT1 and MT2) approved for the treatment of non-24-hour sleep-wake disorder, a circadian rhythm disorder particularly prevalent in totally blind individuals without light perception. It synchronizes the circadian clock by mimicking the endogenous action of melatonin on suprachiasmatic nucleus receptors. It is also being studied for major depressive disorder and other circadian-related conditions.
Berat Molekul
245,3200 g/mol
LogP
2,20
TPSA
38,30 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2
InChI
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
Molecular Formula
C15H19NO2
HBD / HBA
1 / 2
Ikatan yang Dapat Dirotasi
4
Atom Berat
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Tasimelteon is a selective melatonin receptor agonist (MT1 and MT2) approved for the treatment of non-24-hour sleep-wake disorder, a circadian rhythm disorder particularly prevalent in totally blind individuals without light perception. It synchronizes the circadian clock by mimicking the endogenous action of melatonin on suprachiasmatic nucleus receptors. It is also being studied for major depressive disorder and other circadian-related conditions.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Tasimelteon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103822. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10220503. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tasimelteon"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tasimelteon/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tasimelteon/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tasimelteon/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tasimelteon"></drugfyi-drug>